|
Hematologic Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The purpose of this study is to compare the efficacy and safety of three different biosimilars of filgrastim in PBSC mobilization in patients with hematological malignancies.
|
31663634 |
2020 |
|
Hematologic Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
The granulocyte colony stimulating factor (G-CSF) receptor is expressed on the cell surface of some blood cancers such as acute myeloid leukemia (AML).
|
30565075 |
2019 |
|
Hematologic Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
MONITOR-GCSF is a real-world study of 1447 cancer patients receiving CIN/FN prophylaxis with biosimilar filgrastim (solid tumors: 77.2%; hematological malignancies: 22.8%).
|
30827127 |
2019 |
|
Hematologic Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
This includes real-world data from MONITOR-GCSF, a multicenter, prospective, observational study describing treatment patterns and clinical outcomes of patients with cancer (n = 1447) receiving biosimilar filgrastim for the prophylaxis of chemotherapy-induced neutropenia in solid tumors and hematological malignancies.
|
31440986 |
2019 |
|
Hematologic Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Granulocyte colony-stimulating factor and respiratory status of critically ill neutropenic patients with hematologic malignancies.
|
30277108 |
2019 |
|
Hematologic Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Intermediate-dose cytarabine plus G-CSF as mobilization regimen for newly diagnosed multiple myeloma and heavily pre-treated patients with hematological and non-hematological malignancies.
|
30961974 |
2019 |
|
Hematologic Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
We tested the hypothesis that transfusions are associated with the development of severe (grade III-IV) acute graft-versus-host disease (aGVHD) or mortality after allo-HSCT in a retrospective study of 322 consecutive patients receiving an allogeneic bone marrow or granulocyte colony-stimulating factor-mobilized blood stem cell graft for a hematologic malignancy.
|
29307717 |
2018 |
|
Hematologic Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
To test the hypothesis that the content of pDCs in an allograft can be modulated with the cytokines used for mobilization, we randomized the human leukocyte antigen-matched sibling donors of 50 patients with hematological malignancies to a mobilization regimen of either GM+G-CSF (n = 25) or G-CSF alone (n = 25).
|
23201472 |
2013 |
|
Hematologic Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Haploidentical hematopoietic stem cell transplantation in hematologic malignancies with G-CSF mobilized bone marrow plus peripheral blood stem cells grafts without T cell depletion: a single center report of 29 cases.
|
21929286 |
2012 |
|
Hematologic Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The cytokine G-CSF stimulates myeloid progenitors and is routinely used to accelerate neutrophil recovery in the treatment of hematological malignancy and blood or marrow transplantation.
|
19182834 |
2009 |
|
Hematologic Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Haploidentical hematopoietic stem cell transplantation in child hematologic malignancies with G-CSF-mobilized marrow grafts without T-cell depletion: a single-center report of 45 cases.
|
19382033 |
2009 |
|
Hematologic Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
In conclusion, using G-CSF priming marrow grafts along with sequential immunosuppressants provided an excellent alternative for the treatment of high-risk hematological malignancy in patients who lack matched donors.
|
12476277 |
2002 |
|
Hematologic Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Fourteen patients with hematologic malignancies were treated with filgrastim at relapse after alloSCT.
|
10829047 |
2000 |
|
Hematologic Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
In addition, CEA mRNA was amplified in most G-CSF-mobilized PBSC samples derived from patients with hematological malignancies and from healthy donors of allogeneic stem cells, although no circulating epithelial cells could be demonstrated by ICC.
|
10516681 |
1999 |